Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-APP in Early-onset Alzheimer's Disease
NCT05231785Phase 1Recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Feb 2022
- Primary completion
- Jan 2029
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial of mivelsiran in early-onset Alzheimer's disease (EOAD) (3 arms), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Frequency of Adverse Events at 42 months. Started Feb 2022; status: recruiting.
02
Drugs
mivelsiran
03
Conditions
early-onset Alzheimer's disease (EOAD)
Beyond the preview
Go deeper on NCT05231785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05231785.